Cipla has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir, which has been issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat COVID-19 patients.
Arcturus Therapeutics Holdings, a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus.
The M800 multi-parameter transmitter provides simultaneous monitoring of one, two or four in-line sensors. It offers measurement of pH/ORP, optical DO, amperometric oxygen (DO as well as O2 gas), conductivity, resistivity, TOC, dissolved ozone, flow and turbidity in pure water as well as process applications.
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19.
Wavelength Pharmaceuticals, a leading supplier of active pharmaceutical ingredients (APIs), today reported that it has greatly expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients.
The Kluyver Center for Genomics of Industrial Fermentation in Delft, Holland, is a consortium of several different Universities and Research Centres.
Merck announced the US launch of ONTRUZANT (trastuzumab-dttb), as a biosimilar of the reference biologic medicine Herceptin.
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, and Gen, a GMP-certified pharmaceutical company specializing in rare diseases, today announced an exclusive Distribution Agreement for ONPATTRO, a first-in-class RNAi therapeutic for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy.
Amneal Pharmaceuticals, one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.
AstraZeneca has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.